<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894023</url>
  </required_header>
  <id_info>
    <org_study_id>SARD03</org_study_id>
    <nct_id>NCT00894023</nct_id>
  </id_info>
  <brief_title>Intracoronary Abciximab With Clearway Catheter</brief_title>
  <acronym>IC-CLEARLY</acronym>
  <official_title>IntraCoronary Abciximab With the ClearWay Catheter To Improve Outcomes With Lysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gennaro Sardella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Percutaneous coronary intervention (PCI) is a highly effective therapy for acute&#xD;
      ST-elevation myocardial infarction (STEMI). Adjunctive therapy with glycoprotein (GP)&#xD;
      IIb/IIIa inhibitor can result in increased patency and improved outcomes in STEMI patients,&#xD;
      with thrombus, undergoing PCI. The investigation of novel dosing and delivery strategies of&#xD;
      this therapy may help to further improve outcomes.&#xD;
&#xD;
      Study design: Intracoronary Abciximab With Clearway Catheter trial is a randomized,&#xD;
      open-label, multicenter, trial to evaluate the effect of an intracoronary (IC) bolus dose of&#xD;
      abciximab delivered using the ClearWay™RX catheter versus an intravenous bolus (IV) of&#xD;
      abciximab for STEMI with angiographically visible thrombus (Thrombus Grade &gt; 2). All patients&#xD;
      in both arms will receive intravenous abciximab infusion following the PCI for 12 hours per&#xD;
      standard practice. A total of 150 patients will be randomized 1:1 to treatment of the culprit&#xD;
      artery with IC abciximab (75 subjects) or IV abciximab (75 subjects) in addition to an&#xD;
      infusion regimen of abciximab administered intravenously and initiated following PCI. The&#xD;
      primary endpoint chosen to evaluate this hypothesis is infarct size as assessed on Cardiac&#xD;
      Magnetic Resonance (CMR). Clinical outcomes will be assessed for each subject through&#xD;
      hospital discharge and at 30 day follow-up.&#xD;
&#xD;
      Sample size: The number of patients included in this study was based on the estimation of the&#xD;
      sample size needed to identify a statistically significant difference of the primary&#xD;
      end-points between the two groups. The investigators estimated that 75 patients would be&#xD;
      required in each study group to have a power of 80% to detect an absolute difference in the&#xD;
      infarct size resolution of 15% with a two-sided alpha value of 0.05.&#xD;
&#xD;
      Conclusion: The purpose of this study is to demonstrate that an IC bolus of abciximab&#xD;
      delivered with the ClearWay™RX catheter added to a post-PCI intravenous infusion regimen of&#xD;
      abciximab will result in significant additional clot resolution in vivo when compared with an&#xD;
      IV bolus of abciximab when added to a post PCI intravenous infusion regimen of abciximab. The&#xD;
      primary endpoint chosen to evaluate this hypothesis is infarct size as assessed on CMR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the study was stopped because the sample size was very difficult to achieve.&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in infarct size for the IC infusion group compared to the control as measured with cardiac MRI imaging</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic outcomes of lesion, flow, and myocardial perfusion using established and validated Quantitative Coronary Angiographic Methodology</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Abciximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC bolus of abciximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Abciximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV abciximab + infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intracoronary bolus wtih ClearWay™RX catheter</intervention_name>
    <description>Intracoronary bolus with Clearway catheter</description>
    <arm_group_label>Abciximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV abciximab</intervention_name>
    <description>IV abciximab + infusion</description>
    <arm_group_label>IV Abciximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (men or women) at least 18 years of age&#xD;
&#xD;
          2. STEMI: Presenting with ischemic chest discomfort &gt; 20 minutes and &lt;6 hours of duration&#xD;
             suggestive of acute myocardial infarction AND ST elevation &gt; 1 mm (&gt; 0.1 mV) in two&#xD;
             contiguous limb leads OR &gt; 2 mm (&gt; 0.2 mV) in two contiguous precordial leads&#xD;
&#xD;
          3. Must have signed the informed consent form prior to performance of study-related&#xD;
             procedures&#xD;
&#xD;
          4. Native dominant and proximal culprit vessel 2.5 mm in diameter&#xD;
&#xD;
          5. Angiographically identifiable thrombus (presence of a filling defect within the&#xD;
             coronary lumen surrounded by contrast medium observed in multiple projections, without&#xD;
             calcium within the filling defect, or persistence of contrast medium within the&#xD;
             coronary lumen)&#xD;
&#xD;
          6. Pre-PCI Thrombus score (TS) ≥ 2 (angiographically apparent thrombus that is &gt; ½ the&#xD;
             vessel diameter)&#xD;
&#xD;
          7. Pre-PCI TIMI flow grade of 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous PCI of the IRA&#xD;
&#xD;
          2. Previous myocardial infarction or coronary artery bypass grafting&#xD;
&#xD;
          3. Cardiogenic shock&#xD;
&#xD;
          4. Three vessel disease&#xD;
&#xD;
          5. Left main disease&#xD;
&#xD;
          6. Severe valvular heart disease&#xD;
&#xD;
          7. Rescue PCI (PCI following fibrinolytic administration)&#xD;
&#xD;
          8. Facilitated PCI (PCI following fibrinolytic or GP IIb/IIIa inhibition)&#xD;
&#xD;
          9. Contraindication to GP IIb/IIIa inhibitors such as excess bleeding risk or&#xD;
             thrombocytopenia&#xD;
&#xD;
         10. Current participation in another investigational trial&#xD;
&#xD;
         11. Exclusion criteria for the MRI imaging include implanted pacemakers, defibrillators,&#xD;
             or metallic intracranial implants, severe claustrophobia, BMI &gt; 35 kg/m², atrial&#xD;
             fibrillation or known not well controlled extrasystoles (bad images), or allergy to&#xD;
             gadolinium-DTPA&#xD;
&#xD;
         12. Enrolment of patients with an estimated glomerular filtration rate &lt; 30 ml/min/1.73 m2&#xD;
             should be carefully evaluated considering the gadolinium chelate-associated risk of&#xD;
             nephrogenic systemic fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinico of Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept.of Cardiovascular Sciences,Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gennaro Sardella</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Patients with AMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

